+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Symphogen AS - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 23 Pages
  • June 2023
  • GlobalData
  • ID: 1314765
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Symphogen AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.


  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The publisher's summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.


Symphogen A/S (Symphogen) is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics. The product pipeline provides novel approaches to a wide range of cancer types including metastatic colorectal cancer (mCRC), solid tumor malignancies, and lung cancer. The company has collaborations for the development of antibody therapeutics in immuno-oncology with the Shire and infectious disease area with Genentech. It has offices in Denmark and New Jersey, the US. Symphogen is headquartered in Ballerup, Denmark.

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Symphogen A/S - Key Facts
  • Symphogen A/S - Key Employees
  • Symphogen A/S - Key Employee Biographies
  • Symphogen A/S - Major Products and Services
  • Symphogen A/S - History
  • Symphogen A/S - Company Statement
  • Symphogen A/S - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Symphogen A/S - Business Description
  • Symphogen A/S - SWOT Analysis
  • SWOT Analysis - Overview
  • Symphogen A/S - Strengths
  • Symphogen A/S - Weaknesses
  • Symphogen A/S - Opportunities
  • Symphogen A/S - Threats
  • Symphogen A/S - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Symphogen A/S, Recent Deals Summary
Section 4 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Symphogen A/S, Key Facts
  • Symphogen A/S, Key Employees
  • Symphogen A/S, Key Employee Biographies
  • Symphogen A/S, Major Products and Services
  • Symphogen A/S, History
  • Symphogen A/S, Subsidiaries
  • Symphogen A/S, Key Competitors
  • Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Symphogen A/S, Recent Deals Summary
List of Figures
  • Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Symphogen A/S, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023



Companies Mentioned

A selection of companies mentioned in this report includes:

  • Lead Pharma Holding BV
  • 2cureX ApS
  • Bifodan A/S
  • Zealand Pharma AS
  • 2cureX ApS
  • Affitech A/S
  • Bavarian Nordic AS
  • Bifodan A/S
  • CytoVac AS
  • Lead Pharma Holding BV
  • MedAnnex Ltd
  • Mundipharma A/S
  • Nuevolution A/S
  • Roche Innovation Center Copenhagen A/S
  • Zealand Pharma AS
  • Roche Innovation Center Copenhagen A/S
  • MedAnnex Ltd
  • Mundipharma A/S
  • CytoVac AS
  • Nuevolution A/S
  • Bavarian Nordic A/S
  • Affitech A/S